|
|
|
02.10.26 - 22:31
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 02.10.2026 -5- (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026
ISIN Name
US75973T2006 RENALYTIX PLC ADR/50
US79400X6022 DECOY THER.NEW26 DL-,0001
US80880X1046 SCIENTURE HLDGS INC. O.N.
US8293927039 SINTX TEC.INC. NEW DL-,01
US83548F4081 DNA X INC. DL-,001
US83558L3033 SONOMA PHAR. DL0
US84612H3049 SOW GOOD COM PAR DL-,001
US8549362007 STARDUST POWER INC. NEW
US87164U5083 THERIVA BIO. DL-,001
US8761084081 VISIONSYS AI ADR NEW O.N.
US87978U2078 TEMPEST THER.NEW DL-,001
US88583P2039 374WATER INC, NEW O,N,
US8964386036 TRINITY BIOTEC.ADR NEW A
US90915J1034 UNIQUE FABRICAT. DL-,001
US91532B2007 UPHEALTH INC
US91544A2087 UPLAND SOFTW.NEW DL-,0001
US91705J4022 URBAN ONE INC. D N-VTG
US92536C2026 VERU INC. NEW
US92971A1097 WM TECHNOLOGY A DL-,0001
US98420X2027 X4 PHARMACEUTICALS NEW
US98423K4058 XTI AEROSPACE INC. NEW
US98873Q2093 YUNHONG GREEN CTI NEW
USG2...
|
|
|
02.10.26 - 17:24
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
CA86332K4000 Strikepoint Gold Inc. 02.10.2026 CA86332K5098 Strikepoint Gold Inc. 05.10.2026 Tausch 10:1
CA6960732049 Palamina Corp. 02.10.2026 CA69607A1093 Palamina Corp. 05.10.2026 Tausch 1:1
US74933X7084 Catheter Precision Inc. 02.10.2026 US74933X8074 Catheter Precision Inc. 05.10.2026 Tausch 10:1
CA1850536006 Clearmind Medicine Inc. 02.10.2026 CA1850537095 Clearmind Medicine Inc. 05.10.2026 Tausch 8:1
GG00BGJYPP46 Chrysalis Investments Ltd. 02.10.2026 GG00C0GC7Q38 Chrysalis Investments Ltd. 05.10.2026 Tausch 1:1
US80880X1046 Scienture Holdings Inc. 02.10.2026 US80880X2036 Scienture Holdings Inc. 05.10.2026 Tausch 25:1...
|
|
|
|
|
|
|
30.09.26 - 22:06
|
Scienture Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire EN)
|
|
|
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split is expected to take effect before markets open on Monday, October 5, 2026. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol “SCNX” and will begin trading on a split-adjusted basis when the market opens on Monday, October 5, 2026. The new CUSIP number for the Company's common stock following the reverse stock split will be 80880X203. As of September 30, 2026, the Company has 41,064,146 shares of common stock issued ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.05.26 - 14:42
|
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion (GlobeNewswire EN)
|
|
|
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026....
|
|
|
|
|
|
|
|
|
15.04.26 - 14:09
|
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire EN)
|
|
|
COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that on April 14, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price requirement of $1.00 per share. The Company now has until October 12, 2026 to regain compliance, as set forth in Nasdaq Listing Rule 5810(c)(3)(A)....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
